DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors

DE-310 is composed of the topoisomerase-I-inhibitor DX-8951 (exatecan) and a biodegradable macromolecular carrier, which are covalently linked by a peptidyl spacer. In pre-clinical studies, high levels and prolonged retention of conjugated DX-8951 (carrier-bound DX-8951) have been observed in tumor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2005-08, Vol.23 (4), p.339-347
Hauptverfasser:	Wente, Moritz N, Kleeff, Jörg, Büchler, Markus W, Wanders, Jantien, Cheverton, Peter, Langman, Stephen, Friess, Helmut
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Agents, Phytogenic - blood Antineoplastic Agents, Phytogenic - pharmacokinetics Area Under Curve Bone marrow Camptothecin - administration & dosage Camptothecin - analogs & derivatives Camptothecin - blood Camptothecin - pharmacokinetics Cancer Cell growth Delayed-Action Preparations Drug dosages Humans Infusions, Intravenous Male Metastasis Middle Aged Neoplasms - chemistry Neoplasms - metabolism Neoplasms - surgery Permeability Pharmacokinetics Plasma Prodrugs - administration & dosage Prodrugs - pharmacokinetics Radiation therapy Retention Surgery Tissue Distribution Topoisomerase I Inhibitors Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!